RxDoctor Payments Data

Karen Aquino, MD

Neurology · Greensboro, NCNPI 1316147150

Payments from drug & device makers

$8,891in general payments, 2019–2025

Across 527 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • AbbVie$1K
  • Biogen$490
  • SK Life Science, Inc.$338
  • Acadia Pharmaceuticals Inc$333
  • Jazz Pharmaceuticals Inc.$327
  • plus $5K from 54 others

What the payments were for

  • Speaking & faculty fees$891%
  • Food & beverage$8,78599%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.56$1,045
AbbVie(2 entities)81$1,028
Biogen24$490
SK Life Science, Inc.15$338
Acadia Pharmaceuticals Inc36$333
Jazz Pharmaceuticals Inc.14$327
Neurelis, Inc.15$262
Novartis12$237
Grifols USA, LLC11$236
EMD Serono, Inc.9$227
Eisai Inc.9$212
Livanova USA, Inc.6$190
Biohaven Pharmaceuticals, Inc.13$184
Alnylam Pharmaceuticals Inc.10$177
Lundbeck LLC10$176
Supernus Pharmaceuticals, Inc.21$175
Upsher-smith Laboratories LLC11$155
GE HealthCare8$152
Argenx US, Inc.7$150
MDD US Operations, LLC7$149
Sanofi6$139
Sunovion Pharmaceuticals Inc.8$137
Biohaven Pharmaceutical Holding Company Ltd.14$134
Otsuka America Pharmaceutical, Inc.6$130
Banner Life Sciences, LLC5$105
AstraZeneca5$103
Mallinckrodt Hospital Products Inc.4$91
Acorda Therapeutics, Inc4$89
Neurocrine Biosciences, Inc.4$87
Pfizer5$83
Aquestive Therapeutics, Inc.5$74
Lilly USA, LLC4$73
Boston Scientific3$68
Abbott4$65
Takeda Pharmaceuticals U.S.A., Inc.2$63
Catalyst Pharmaceuticals, Inc.3$62
Johnson & Johnson4$61
Corium, LLC3$60
Sumitomo Pharma America, Inc.13$58
Merz North America, Inc.2$58
Greenwich Biosciences, Inc.3$53
Merz Pharmaceuticals, LLC2$52
Teva Pharmaceuticals USA, Inc.3$51
Medtronic(2 entities)3$49
Impel Pharmaceuticals Inc.3$45
Genentech USA, Inc.2$43
TG Therapeutics, Inc.1$43
Impel Pharmaceuticals LLC2$41
Amneal Pharmaceuticals LLC3$41
Octapharma USA, Inc.2$40
Collegium Pharmaceutical, Inc.2$39
Amgen2$38
Aucta Pharmaceuticals, Inc.2$34
Bristol Myers Squibb2$33
Vertical Pharmaceuticals, LLC2$29
Merck1$29
C2n Diagnostics, LLC1$25
Adamas Pharmaceuticals, Inc.1$24
Bausch Health US, LLC1$24
ANI Pharmaceuticals, Inc.1$23

How this compares

$8,891 in reported general payments places this provider in the 70th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$35,759
Medicare patients
147
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LamictalLamotrigine35$74,109
VimpatLacosamide31$59,922
BriviactBrivaracetam35$57,533
XcopriCenobamate34$40,053
KeppraLevetiracetam18$38,559
TrileptalOxcarbazepine17$37,106
AptiomEslicarbazepine Acetate13$29,943
FycompaPerampanel15$22,521
NuedextaDextromethorphan Hbr/Quinidine12$21,972
UbrelvyUbrogepant15$15,704
Levetiracetam471$14,493
Aimovig AutoinjectorErenumab-Aooe16$12,020
Lacosamide92$9,717
Oxcarbazepine116$9,413
Emgality PenGalcanezumab-Gnlm13$9,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Vimpat, Briviact$1,045$117,45566 claims
SK Life Science, Inc.Xcopri$338$40,05334 claims
Sunovion Pharmaceuticals Inc.Aptiom$137$29,94313 claims
Eisai Inc.Fycompa$212$22,52115 claims
AbbVieUbrelvy$1,028$15,70415 claims
PfizerDilantin$83$8,88240 claims
Upsher-smith Laboratories LLCTopiramate$155$2,050123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 566 neurology providers in North Carolina.

Other neurology in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →